212 patents
Page 5 of 11
Utility
Methods for Purification of Messenger Rna
5 May 22
The present invention provides, among other things, methods of purifying messenger RNA (mRNA) including the steps of (a) precipitating mRNA from an impure preparation; (b) subjecting the impure preparation comprising precipitated mRNA to a purification process involving membrane filtration such that the precipitated mRNA is captured by a membrane; and (c) eluting the captured precipitated mRNA from the membrane by re-solubilizing the mRNA, thereby resulting in a purified mRNA solution.
Frank DeRosa, Anusha Dias, Shrirang Karve, Michael Heartlein
Filed: 10 Jun 21
Utility
Large Scale Synthesis of Messenger RNA
5 May 22
The present invention provides, among other things, methods for large-scale production of a composition comprising full-length messenger RNA product that is substantially free of double-stranded RNA, and compositions produced using such methods and uses thereof.
Jonathan Abysalh, Anusha Dias, Jorel E. Vargas, Dustin Cooper, Frank DeRosa
Filed: 15 Oct 21
Utility
Process of Preparing Ice-based Lipid Nanoparticles
5 May 22
The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation.
Monic Shah, Travis Jeanotte, Yi Zhang, Shrirang Karve, Kimberly Gillis, Frank DeRosa
Filed: 12 Oct 21
Utility
Process of Preparing Mrna-loaded Lipid Nanoparticles
14 Apr 22
The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation.
Shrirang Karve, Travis Jeanotte, Monic Shah, Yi Zhang, Kimberly Gillis, Frank DeRosa
Filed: 12 Oct 21
Utility
Lipid Nanoparticle Compositions and Methods for Mrna Delivery
14 Apr 22
Disclosed herein are compositions and methods for modulating the production of a protein in a target cell.
Braydon Charles Guild, Frank DeRosa, Michael Heartlein
Filed: 20 Dec 21
Utility
Lipid Nanoparticle Compositions and Methods for Mrna Delivery
14 Apr 22
Disclosed herein are compositions and methods for modulating the production of a protein in a target cell.
Braydon Charles Guild, Frank DeRosa, Michael Heartlein
Filed: 20 Dec 21
Utility
Lipid Nanoparticle Compositions and Methods for Mrna Delivery
14 Apr 22
Disclosed herein are compositions and methods for modulating the production of a protein in a target cell.
Braydon Charles Guild, Frank DeRosa, Michael Heartlein
Filed: 21 Dec 21
Utility
Liver Specific Delivery of Messenger Rna
14 Apr 22
Disclosed herein are compositions and methods of modulating the expression of gene or the production of a protein by transfecting target cells with nucleic acids.
Braydon Charles Guild, Frank DeRosa, Michael Heartlein
Filed: 21 Dec 21
Utility
Liver Specific Delivery of Messenger Rna
14 Apr 22
Disclosed herein are compositions and methods of modulating the expression of gene or the production of a protein by transfecting target cells with nucleic acids.
Braydon Charles Guild, Frank DeRosa, Michael Heartlein
Filed: 22 Dec 21
Utility
Liver Specific Delivery of Messenger Rna
14 Apr 22
Disclosed herein are compositions and methods of modulating the expression of gene or the production of a protein by transfecting target cells with nucleic acids.
Braydon Charles Guild, Frank DeRosa, Michael Heartlein
Filed: 22 Dec 21
Utility
Lipid nanoparticle compositions and methods for mRNA delivery
5 Apr 22
Disclosed herein are compositions and methods for modulating the production of a protein in a target cell.
Braydon Charles Guild, Frank DeRosa, Michael Heartlein
Filed: 25 Oct 21
Utility
Composition and Methods for Treatment of Primary Ciliary Dyskinesia
24 Mar 22
The present invention provides, among other things, methods and compositions for treating primary ciliary dyskinesia (PCD) based on mRNA therapy.
Anusha Dias, Darshan Parekh, Jeffrey S. Dubins, Christian Cobaugh, Shrirang Karve, Zarna Patel, Sara J. Dunaj, Frank DeRosa, Michael Heartlein
Filed: 7 Jan 20
Utility
Peg Lipidoid Compounds
10 Mar 22
The compounds disclosed herein (e.g., compounds having a structure according to Formula (I/(II)/(III)/(IV), and (V)) are polymers wherein an organic polymeric segment (e.g., a polyethylene glycol (PEG) group) comprises covalent attachments to two or more lipid substructures, and each lipid substructure independently comprises a hydrophobic moiety and a hydrophilic moiety.
Shrirang Karve, Yi Zhang, Frank DeRosa, Michael Heartlein
Filed: 7 Nov 19
Utility
Composition and Methods for Treatment of Ornithine Transcarbamylase Deficiency
10 Mar 22
The present invention provides, among other things, methods of treating ornithine transcarbamylase deficiency, including administering to a subject in need of treatment a composition comprising an mRNA encoding an ornithine transcarbamylase protein at a low dose and at an administration interval such that at least one symptom or feature of the OTC deficiency is reduced.
Kim Askew, Jou-Ku Chung, Frank DeRosa, Michael Heartlein, Shrirang Karve, Thomas McCauley, Lianne Smith, Ann J. Barbier
Filed: 27 Sep 21
Utility
Multimeric Coding Nucleic Acid and Uses Thereof
10 Mar 22
The present invention provides, among other things, multimeric coding nucleic acids that exhibit superior stability for in vivo and in vitro use.
Frank DeRosa, Michael Heartlein, Daniel Crawford, Shrirang Karve
Filed: 17 Aug 21
Utility
mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
24 Feb 22
Compositions for modulating the expression of a protein in a target cell comprising at least one RNA molecule which comprises at least one modification 5 conferring stability to the RNA, as well as related methods, are disclosed.
Braydon Charles Guild, Michael Heartlein, Frank DeRosa
Filed: 2 Sep 21
Utility
Nucleic acid conjugates and uses thereof
22 Feb 22
Provided herein are conjugates comprising targeting moieties such as sugars, folates and cell-penetrating peptides, which can be used for the improved delivery of agents (e.g., nucleic acids, such as oligonucleotides or mRNAs, or other agents) to cells.
Balkrishen Bhat, Saswata Karmakar, Debatosh Majumdar, Jia Tay, Nelson Chau
Filed: 11 Jul 17
Utility
Codon-optimized CFTR MRNA
22 Feb 22
The present invention provides, among other things, improved methods and pharmaceutical compositions for treating cystic fibrosis based on codon optimized mRNA encoding a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein.
Anusha Dias, Jonathan Abysalh, Brian Bettencourt, Frank DeRosa, Michael Heartlein
Filed: 27 Feb 18
Utility
Nuclease resistant polynucleotides and uses thereof
22 Feb 22
The invention provides, among other things, methods of stabilizing mRNA and nuclease resistant mRNA prepared in accordance with such methods.
Michael Heartlein, Braydon Charles Guild, Frank DeRosa
Filed: 18 May 18
Utility
Stereochemically Enriched Compositions for Delivery of Nucleic Acids
17 Feb 22
Frank DeRosa, Shrirang Karve, Michael Heartlein
Filed: 22 Jul 21